Glaucoma – Executive Insights – Glaucoma | Executive Insights (US)

launch Related Market Assessment Reports

• Biosimilars – Forecast – Endocrinology

  September 2023

  In 2021, sales of insulins at the ex-manufacturer price level exceeded $20 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast…

• Biomarkers In Oncology – Access & Reimbursement – Detailed, Expanded Analysis: Biomarkers In Oncology – Non-Small-Cell Lung Cancer, Breast Cancer, And Colorectal Cancer (US)

  Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

• Biosimilars – Forecast – Respiratory

  In 2021, sales of branded biologics for respiratory indications totaled about $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…

• Biosimilars – Forecast – Ophthalmology

  In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the…

• Biosimilars – Forecast – Overview Of Biosimilar Forecasts

  In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…